The EPS miss and accelerating cash burn are incremental negatives for a pre-revenue biotech, but the stock has historically rallied on neutral news. The key catalyst is the C-BEYOND HCV data readout mid-2026 — positive results could drive significant upside. Traders should watch for insider buying/selling patterns ahead of the data readout and consider the $256M cash runway (roughly 5-6 quarters at current burn rate).
Price Chart
Executive Summary
Atea Pharmaceuticals reported Q1 2026 EPS of -$0.57, a 2.7% miss vs consensus of -$0.56, with net loss widening to $45.4M from $34.3M a year ago. The company highlighted upcoming Phase 3 HCV data readouts (C-BEYOND mid-2026, C-FORWARD year-end 2026) and plans to initiate a Phase 1 HEV program mid-2026, but the quarter showed no revenue and increased R&D spend. The stock has historically rallied on neutral reports, but the EPS miss and cash burn acceleration are incremental negatives.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.57 vs consensus -$0.56 (2.7% miss)
- Net loss widened to $45.4M from $34.3M in Q1 2025
- Cash and marketable securities fell to $256.0M from $301.8M at year-end 2025
- R&D expenses increased 39% to $41.1M driven by HCV Phase 3 and HEV preclinical work
- No revenue reported; pre-revenue biotech with no approved products
- Phase 3 HCV trial C-BEYOND topline results expected mid-2026
- Phase 1 HEV program for AT-587 expected to initiate mid-2026
Financial Impact
Net loss of $45.4M in Q1 2026 vs $34.3M in Q1 2025; cash burn of ~$45.8M in the quarter
Risk Factors
- HCV Phase 3 data may fail to meet primary endpoint or show inferiority vs sofosbuvir/velpatasvir
- Cash burn rate may require dilutive financing before data readouts
- HEV program is preclinical with no guarantee of clinical success
- Competition from established HCV treatments (Gilead, AbbVie) limits commercial opportunity even if approved
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293389 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | SC 13G | $5.01 | awaiting T+60 | — | $4.16 (−16.97%) |
Jul 14, 2026 14w ago | Press Release | $4.70 $5.01 | ▲ +6.60% | ▲ +3.22% | $4.16 (−11.49%) |
May 12, 2026 23w ago | Press Release | $4.57 $5.25 | ▼ −14.88% | ▼ −10.44% | $4.16 (+8.97%) |
Apr 27, 2026 26w ago | DEFA14A | $5.58 $4.75 | ▼ −14.87% | ▼ −18.86% | $4.16 (−25.45%) |
Mar 5, 2026 33w ago | 8-K | $5.89 $4.38 | ▼ −25.64% | ▼ −38.42% | $4.16 (−29.37%) |
Mar 5, 2026 33w ago | Press Release | $5.89 $4.38 | ▼ −25.64% | ▼ −38.42% | $4.16 (−29.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers